Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD 384.00
+6.00 (1.59%)
Jul 30, 2026, 1:30 PM CST
Bora Pharmaceuticals Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48,143 | 60,524 | 77,712 | 64,612 | 31,121 | 12,446 | |
Market Cap Growth | -44.26% | -22.12% | 20.27% | 107.61% | 150.04% | 17.05% |
Enterprise Value | 62,862 | 77,667 | 92,091 | 67,752 | 36,584 | 13,828 |
Last Close Price | 378.00 | 488.00 | 615.75 | 515.21 | 254.86 | 101.35 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.23 | 20.30 | 20.17 | 21.32 | 22.36 | 16.60 |
Forward PE | 13.97 | 11.87 | 16.07 | 21.03 | 11.57 | 14.97 |
PS Ratio | 2.60 | 3.18 | 4.46 | 4.55 | 2.97 | 2.54 |
PB Ratio | 2.90 | 3.46 | 5.21 | 5.49 | 6.05 | 3.95 |
P/TBV Ratio | 5.76 | 6.62 | 14.83 | 18.95 | 13.07 | 4.18 |
P/FCF Ratio | 17.46 | 16.93 | 171.96 | 14.97 | 17.14 | 11.60 |
P/OCF Ratio | 12.75 | 13.44 | 79.30 | 14.01 | 15.48 | 10.07 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.39 | 4.09 | 5.28 | 4.77 | 3.49 | 2.82 |
EV/EBITDA Ratio | 17.68 | 18.43 | 20.17 | 11.82 | 16.87 | 11.42 |
EV/EBIT Ratio | 24.58 | 23.58 | 24.84 | 12.91 | 19.03 | 13.22 |
EV/FCF Ratio | 22.80 | 21.73 | 203.78 | 15.70 | 20.15 | 12.89 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.06 | 1.04 | 1.27 | 0.42 | 1.48 | 0.70 |
Debt / EBITDA Ratio | 4.37 | 4.22 | 4.06 | 0.86 | 3.44 | 1.80 |
Debt / FCF Ratio | 6.36 | 5.10 | 41.98 | 1.16 | 4.18 | 2.07 |
Net Debt / Equity Ratio | 0.76 | 0.75 | 0.88 | 0.14 | 0.79 | 0.42 |
Net Debt / EBITDA Ratio | 3.23 | 3.11 | 2.86 | 0.28 | 1.88 | 1.08 |
Net Debt / FCF Ratio | 4.59 | 3.66 | 28.89 | 0.37 | 2.24 | 1.22 |
Asset Turnover | 0.40 | 0.42 | 0.49 | 0.59 | 0.70 | 0.68 |
Inventory Turnover | 2.85 | 2.51 | 2.52 | 3.48 | 5.19 | 3.16 |
Quick Ratio | 1.04 | 1.11 | 1.24 | 0.91 | 0.95 | 0.96 |
Current Ratio | 1.38 | 1.45 | 1.69 | 1.29 | 1.17 | 1.52 |
Return on Equity (ROE) | 10.98% | 27.46% | 31.61% | 36.34% | 33.80% | 26.69% |
Return on Assets (ROA) | 4.10% | 4.56% | 6.56% | 13.70% | 7.97% | 9.10% |
Return on Invested Capital (ROIC) | 7.09% | 9.48% | 14.49% | 35.16% | 21.42% | 16.76% |
Return on Capital Employed (ROCE) | 9.70% | 10.50% | 11.70% | 31.10% | 15.70% | 18.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.34% | 4.93% | 4.96% | 4.69% | 4.47% | 6.02% |
FCF Yield | 5.73% | 5.91% | 0.58% | 6.68% | 5.83% | 8.62% |
Dividend Yield | 2.64% | 2.05% | 1.90% | 1.94% | 2.01% | 2.01% |
Payout Ratio | 90.11% | 48.60% | 32.00% | 20.43% | 17.16% | 14.64% |
Buyback Yield / Dilution | -30.55% | -33.62% | -13.61% | -4.93% | -1.41% | -0.86% |
Total Shareholder Return | -28.03% | -31.57% | -11.71% | -2.99% | 0.61% | 1.16% |